Anatara Lifesciences Ltd (ASX:ANR) develops evidence-based health products for conditions with significant unmet need, with a particular focus on the gastrointestinal tract. The company released its Appendix 4C and Q4 FY26 activities report for the quarter ended June 2026 on 31 July 2026, covering its anti-obesity project, its GaRP product, cash movements and an R&D tax incentive claim.

Anti-obesity project

The project aims to develop an oral complementary medication to help maintain weight loss and limit rebound weight gain after stopping medications such as GLP-1 agonists, including semaglutide. The compounds of interest are classified as Generally Regarded As Safe (GRAS) and suited to a complementary medicine or nutraceutical. The company said the project had been on hold while negotiations on other transactions progressed.

In pre-clinical studies at the University of Newcastle, a candidate compound referred to as AOC showed two independent measures suggesting activity of statistical significance. Compared with a placebo vehicle, AOC significantly reduced weight gain in the weeks after stopping injectable semaglutide, with a p-score below 0.019, and reduced perigonadal fat weight (n=12, p=0.024). The mechanism of action studies, completed in February 2026 after a delay from unavailability of an assay kit, were inconclusive about a direct effect on endogenous GLP-1 levels.

The company has spent more than $350,000 on the proof-of-concept studies and is considering an open label trial of AOC in healthy volunteers. The design is under review, taking into account commercial potential, endpoints and the route to market.

GaRP and corporate activity

Manuscripts on the GaRP project pre-clinical work and the IBS clinical trial have been submitted for review. GaRP is a multi-component complementary medicine intended to assist the gastrointestinal lining and microbiome in conditions such as IBS and IBD. The company says there remains commercial interest in the GaRP intellectual property. It also continues Business development discussions, including potential M&A, and is evaluating other opportunities in the junior healthcare sector.

Cash flow and R&D incentive

Cash at the end of the quarter was $0.471 million, compared with $0.707 million at 31 March. Net operating cash outflows were $0.286 million, compared with $0.327 million in the previous quarter. Payments to related parties, which include directors' fees and superannuation, totalled $92,000.

After the quarter, on 28 July 2026, the company lodged its 2026 registration for the R&D tax incentive with AusIndustry. It anticipates processing through August and a rebate of more than $300,000.

Study design and spending

The in-vivo experiments at the University of Newcastle used diet-induced obese mice to observe weight loss control and maintenance in response to therapeutic inputs. The study assessed proprietary drug candidates and GLP-1 receptor agonists. The candidate compounds targeted endogenous stimulation of GLP-1 production, and dosage regimes were predicted from published pre-clinical and clinical studies. The company said perigonadal fat is highly indicative of visceral fat deposits and the likelihood of metabolic conditions.

The company said it continues to maintain financial control over operations while it reviews other opportunities and Assets to enhance its portfolio of projects.

Risks and sector context

The company is pre-revenue, and cash of $0.471 million compares with quarterly operating outflows of $0.286 million. The expected R&D rebate is anticipated and depends on processing. The anti-obesity data are from animal studies, and the mechanism of action work was inconclusive, so human effect has not been tested. The trial design is still under review and no trial has been announced. The report does not announce a transaction, and discussions on M&A or IP commercialisation are described as ongoing.

For sector context, the company references the weight management market and the use of GLP-1 medications, and aims to address maintenance after stopping them.

What to watch next

Items to watch include the outcome of the R&D tax incentive claim, a decision on an open label trial of AOC, publication of the GaRP manuscripts, any transaction arising from business development discussions, and the company's cash position in the next quarterly report.